No Picture
News

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Pulmazole is on track for Phase 2b study start in Q1 2023 PUR3100 Phase 1 study is underway with data anticipated in Q4 2022 Ends Q2 with $42.9 million in cash and cash equivalents LEXINGTON, Mass., Aug. 8, 2022 /PRNewswire/ — Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage… Click here to view original post… […]

No Picture
News

Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sesen Bio (Nasdaq: SESN) today reported operating results for the second quarter ended June 30, 2022. During the quarter, the Company paused clinical development of its lead asset, Vicineum™ for the treatment of non-muscle invasive bladder cancer (NMIBC), and turned its primary focus to the assessment of potential… Click here to view original post… […]

No Picture
News

Review of SURPASS-ET Trial Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia (ET) Published in Future Oncology

BURLINGTON, Mass.–(BUSINESS WIRE)–PharmaEssentia’s SURPASS-ET trial protocol evaluating ropeginterferon alfa-2b-njft in essential thrombocythemia (ET) is published in Future Oncology. Click here to view original post… […]

No Picture
News

VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass.–(BUSINESS WIRE)–VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced financial results for the second quarter ending June 30, 2022 and provided a corporate update. Jeff Baxter, VBI’s President and CEO commented: “Since the… Click here to view original post… […]

No Picture
News

Initial Analysis of Tumor Profiling From a Prospective Study by Foundation Medicine, Flatiron Health and Genentech Demonstrates Value of Tissue and Liquid Comprehensive Genomic Profiling in Patients with Advanced Non-Small Cell Lung Cancer

CAMBRIDGE, Mass. & NEW YORK–(BUSINESS WIRE)–The ongoing real-world PCG Study compares the clinical actionability of both tissue- and blood-based CGP to limited tissue testing in aNSCLC Click here to view original post… […]